GlassScriptPhysician profile
Surinder M Kaura
NPI 1750387056
$3,860.70
in general payments reported to CMS, 2019-2025
29 companies · $519 in 2025
The $519 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $508 · 2020: $496 · 2021: $727 · 2022: $439 · 2023: $688 · 2024: $483 · 2025: $519.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,690.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,690.21 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $843.91 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Abbvie INC. | $521.63 | 2020-2024 | |
| Pfizer INC. | $364.48 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $338.24 | 2019-2025 | Airsupra, Breztri, Farxiga |
| Boehringer Ingelheim Pharmaceuticals, INC. | $177.79 | 2019-2025 | Jardiance |
| Lilly USA, LLC | $161.76 | 2019-2025 | Zepbound, Mounjaro, Jardiance |
| Allergan, INC. | $159.39 | 2019-2020 | |
| Sumitomo Pharma America, INC. | $117.69 | 2023-2025 | Gemtesa |
| Sunovion Pharmaceuticals INC. | $117.36 | 2021-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $112.04 | 2019-2022 | |
| Amarin Pharma, INC. | $111.62 | 2020-2021 | |
| Amgen INC. | $105.60 | 2021-2025 | Otezla, Repatha, Otezla |
| Lundbeck LLC | $94.66 | 2020-2025 | Rexulti |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $94.08 | 2025 | Caplyta |
| Exact Sciences Corporation | $90.88 | 2023-2025 | Cologuard Collection Kit |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic Vascular, INC. | $76.79 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $63.31 | 2019-2024 | Xifaxan |
| Novo Nordisk INC | $57.88 | 2019-2025 | Ozempic, Rybelsus |
| Otsuka America Pharmaceutical, INC. | $54.59 | 2024-2025 | Rexulti |
| Axsome Therapeutics, INC. | $35.76 | 2023 | Auvelity |
| Biohaven Pharmaceuticals, INC. | $28.94 | 2021 | |
| Novartis Pharmaceuticals Corporation | $27.54 | 2021-2022 | |
| Circassia INC. | $26.44 | 2019-2020 | |
| Aimmune Therapeutics, INC. | $14.51 | 2024 | |
| Shield Therapeutics INC | $14.29 | 2025 | |
| Nestle Healthcare Nutrition INC. | $13.72 | 2023 | |
| Horizon Therapeutics Plc | $12.30 | 2022 | |
| Xeris Pharmaceuticals, INC. | $12.02 | 2022 | |
| Astellas Pharma US INC | $11.48 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Surinder Kaura listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.